Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma

Giao N. Le, Jonathan Bones, Mark Coyne, Despina Bazou, Paul Dowling, Peter O'Gorman, Anne Marie Larkin

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)

Abstract

Multiple myeloma, an incurable malignancy of the plasma cells in the bone marrow, has a complex pathogenesis due to clonal heterogeneity. Over the years, many clinical trials and researches have led to the development of effective myeloma treatments, resulting in survival prolongation. Molecular prognostic markers for risk-stratification to predict survival, and predictive markers for treatment response are being extensively explored. This review discusses the current risk-adaptive strategies based on genetic and molecular risk signatures that are in practice to predict survival and describes the future prognostic and predictive biomarkers across the fields of genomics, proteomics, and glycomics in myeloma. Gene expression profiling and next generation sequencing are coming to the forefront of risk-stratification and therapeutic-response prediction. Similarly, proteomic and glycomic-based platforms are gaining momentum in biomarker discovery to predict drug resistance and disease progression.

Original languageEnglish
Pages (from-to)7-20
Number of pages14
JournalMolecular Omics
Volume15
Issue number1
DOIs
Publication statusPublished - 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma'. Together they form a unique fingerprint.

Cite this